0.10Open0.10Pre Close0 Volume43 Open Interest2.00Strike Price0.00Turnover7295.78%IV103.88%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier-1DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type0.2943Delta0.4572Gamma10.30Leverage Ratio-3.5626Theta0.0000Rho3.03Eff Leverage0.0000Vega
Gossamer Bio Stock Discussion
loading...
loading...
Gossamer Bio a new outperform at Oppenheimer on seralutinib for PAH
• Oppenheimer has initiated Gossamer Bio at outperform expressing optimism on seralutinib, its inhaled tyrosine kinase inhibitor for pulmonary arterial hypertension (PAH).
• The firm has a $9 price target (~984% upside based on June 24 close).
• Analyst Andreas Argyrides said that the candidate's safety and efficacy profile makes it "a preferred choice among severe PAH patients who are not ad...
No comment yet